BI 1479-0001: Anti-HER2 TKI BI 1810631 for the Treatment of HER2 Mutant NSCLC

Condition: Non-Small Cell Lung Cancer

Sponsor: Boehringer Ingelheim

Full Title
1479-0001: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of BI 1810631 as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations

Study Treatment
Anti-HER2 tyrosine kinase inhibitor BI 1810631

Eligibility/Info
Phase 1b, Cohort 1: Advanced or metastatic NSCLC with HER2 mutation in the tyrosine kinase domain (exons 18-21) with progressive disease after platinum-based chemotherapy and any relevant targeted therapies
Phase 1b, Cohort 2: Advanced or metastatic NSCLC with HER2 mutation in the tyrosine kinase domain (exons 18-21) without prior treatment in the metastatic setting
Phase 1b, Cohort 3: Advanced or metastatic NSCLC with HER2 mutation (non-TKD) with progressive disease after platinum-based chemotherapy and any relevant targeted therapies

Contact
For more information you may contact the Research Department through the NYCBS HALO Messaging Center or call directly: 631-675-5075.